tiprankstipranks
Trending News
More News >
ImmunityBio (IBRX)
NASDAQ:IBRX
Advertisement

ImmunityBio (IBRX) Stock Statistics & Valuation Metrics

Compare
1,537 Followers

Total Valuation

ImmunityBio has a market cap or net worth of $2.26B. The enterprise value is $3.03B.
Market Cap$2.26B
Enterprise Value$3.03B

Share Statistics

ImmunityBio has 945,254,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding945,254,700
Owned by Insiders69.21%
Owned by Institutions2.54%

Financial Efficiency

ImmunityBio’s return on equity (ROE) is 0.85 and return on invested capital (ROIC) is -102.24%.
Return on Equity (ROE)0.85
Return on Assets (ROA)-1.08
Return on Invested Capital (ROIC)-102.24%
Return on Capital Employed (ROCE)-1.05
Revenue Per Employee21.97K
Profits Per Employee-616.46K
Employee Count671
Asset Turnover0.04
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of ImmunityBio is ―. ImmunityBio’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value-3.66
Price to FCF
Price to Operating Cash Flow-6.05
PEG Ratio

Income Statement

In the last 12 months, ImmunityBio had revenue of 14.74M and earned -413.56M in profits. Earnings per share was -0.59.
Revenue14.74M
Gross Profit14.74M
Operating Income-344.18M
Pretax Income-413.56M
Net Income-413.56M
EBITDA-241.76M
Earnings Per Share (EPS)-0.59

Cash Flow

In the last 12 months, operating cash flow was -349.56M and capital expenditures -7.11M, giving a free cash flow of -356.66M billion.
Operating Cash Flow-349.56M
Free Cash Flow-356.66M
Free Cash Flow per Share-0.38

Dividends & Yields

ImmunityBio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta2.10
52-Week Price Change-29.29%
50-Day Moving Average2.58
200-Day Moving Average2.97
Relative Strength Index (RSI)46.71
Average Volume (3m)9.08M

Important Dates

ImmunityBio upcoming earnings date is Nov 7, 2025, TBA (Confirmed).
Last Earnings DateAug 5, 2025
Next Earnings DateNov 7, 2025
Ex-Dividend Date

Financial Position

ImmunityBio as a current ratio of 3.36, with Debt / Equity ratio of -93.79%
Current Ratio3.36
Quick Ratio3.21
Debt to Market Cap0.42
Net Debt to EBITDA-1.49
Interest Coverage Ratio-2.23

Taxes

In the past 12 months, ImmunityBio has paid 81.00K in taxes.
Income Tax81.00K
Effective Tax Rate>-0.01

Enterprise Valuation

ImmunityBio EV to EBITDA ratio is -8.88, with an EV/FCF ratio of -5.39.
EV to Sales145.53
EV to EBITDA-8.88
EV to Free Cash Flow-5.39
EV to Operating Cash Flow-5.48

Balance Sheet

ImmunityBio has $153.66M in cash and marketable securities with $535.32M in debt, giving a net cash position of $381.66M billion.
Cash & Marketable Securities$153.66M
Total Debt$535.32M
Net Cash$381.66M
Net Cash Per Share$0.40
Tangible Book Value Per Share-$0.72

Margins

Gross margin is 99.66%, with operating margin of -2334.23%, and net profit margin of -2804.77%.
Gross Margin99.66%
Operating Margin-2334.23%
Pretax Margin-2804.77%
Net Profit Margin-2804.77%
EBITDA Margin-1639.63%
EBIT Margin-1758.68%

Analyst Forecast

The average price target for ImmunityBio is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.00
Price Target Upside234.73% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast4227.22%
EPS Growth Forecast50.80%

Scores

Smart Score5
AI Score46
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis